Incidence of Colorectal Adenomas: Birth Cohort Analysis Among 4.3 Million Participants of Screening Colonoscopy
Overview
Oncology
Public Health
Affiliations
Background: Most colorectal cancers develop from adenomas. We aimed to estimate sex- and age-specific incidence rates of colorectal adenomas and to assess their potential implications for colorectal cancer screening strategies.
Methods: Sex- and age-specific incidence rates of colorectal adenomas were derived by a birth cohort analysis using data from 4,322,085 screening colonoscopies conducted in Germany and recorded in a national database in 2003-2012. In addition, cumulative risks of colorectal cancer among colonoscopically neoplasm-free men and women were estimated by combining adenoma incidence rates with previously derived adenoma-colorectal cancer transition rates.
Results: Estimated annual incidence in percentage (95% confidence interval) in age groups 55-59, 60-64, 65-69, 70-74, and 75-79 was 2.4 (2.2-2.6), 2.3 (2.1-2.6), 2.4 (2.1-2.6), 2.2 (1.8-2.5), and 1.8 (1.2-2.3) among men, and 1.4 (1.3-1.5), 1.5 (1.4-1.7), 1.6 (1.4-1.8), 1.6 (1.3-1.8), and 1.2 (0.8-1.6) among women. Estimated 10- and 15-year risks of clinically manifest colorectal cancer were 0.1% and 0.5% or lower, respectively, in all groups assessed.
Conclusions: Annual incidence rates of colorectal adenomas are below 2.5% and 2% among men and women, respectively, and show little variation by age.
Impact: Risk of clinically manifest colorectal cancer is expected to be very small within 10 years and beyond after negative colonoscopy for men and women at all ages. The use of rescreening after a negative screening colonoscopy above 60 years of age may be very limited.
Ciulei G, Orasan O, Cozma A, Negrean V, Para I, Ciumarnean L Int J Mol Sci. 2024; 25(16).
PMID: 39201651 PMC: 11354587. DOI: 10.3390/ijms25168965.
Rosas U, Pan J, Sundaram V, Su A, Fazal M, Dinh P Gastro Hep Adv. 2024; 2(1):132-143.
PMID: 39130145 PMC: 11307611. DOI: 10.1016/j.gastha.2022.07.014.
Yu M, Ouyang Y, Yuan Z, Wang S, Pang W, Yan S Sci Rep. 2024; 14(1):11633.
PMID: 38773186 PMC: 11109095. DOI: 10.1038/s41598-024-62348-w.
Colorectal cancer screening-what does the recent NordICC trial mean for the U.S. population?.
Das T, Rauch J, Shaukat A Transl Gastroenterol Hepatol. 2023; 8:40.
PMID: 38021363 PMC: 10643301. DOI: 10.21037/tgh-23-20.
Barnett M, Wassie M, Cock C, Bampton P, Symonds E Dig Dis Sci. 2023; 68(11):4243-4251.
PMID: 37682374 PMC: 10570165. DOI: 10.1007/s10620-023-08053-6.